Announcement on Convening Performance Briefing for 2025 and Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening Performance Briefing for 2025 and Q1 2026
Filed with SSE · · 3 pages · Chinese
Release
Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd on 6ix
Earlier from Hangzhou Tianmushan Pharmaceutical Enterprise
- Announcement on Resolutions of the 2025 Annual General Meeting
- Report for Q1 2026
- Announcement on Purchasing Liability Insurance for Directors and Senior Management Members
- Announcement on Progress in Guarantees Provided for the Company's and Its Subsidiary's Application for Comprehensive Credit Line from Banks and Other Financial Institutions in 2025
- Announcement on Abnormal Fluctuations in Stock Trading
Later from Hangzhou Tianmushan Pharmaceutical Enterprise
- Announcement on Listing and Circulation of Shares Subject to Lock-Up from Shareholding Reform
- Announcement on Resolutions of the 20th Meeting of the 12th Board of Directors
- Announcement on Reply to Letter of Supervision and Inquiry of 2025 Annual Report
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Indicative Announcement on Proposed Transfer of Part of Company's Shares by Controlling Shareholder through Public Solicitation and Possible Change in Control
Follow Hangzhou Tianmushan Pharmaceutical Enterprise into a list and get an email when it puts out news.
Follow Hangzhou Tianmushan Pharmaceutical Enterprise